As HTS has matured, the understanding of what features constitute a quality hit and lead has evolved. Over recent years an industry of compound suppliers has grown to provide drug discovery with screening compounds: it's estimated that there are over 16 million compounds available from these sources. It is generally regarded that low lipophilic, and higher fsp3 properties are preferred. This paper reviews the chemical space covered by suppliers' compound libraries (SCL) in terms of compound chemophysical properties, novelty, diversity and quality. It examines the feasibility of compiling high-quality vendor-based libraries avoiding complicated, expensive compound management activity and compares the resulting libraries to the ChEMBL dataset. From our analysis it would appear that over the last 10 years the market has evolved to meet these demands, with new compounds from many suppliers meeting modern physiochemical properties. At the moment it is not possible to purchase an ideal one-million compound set (50K scaffolds, minimum of 20 compounds per scaffold). However, it would appear that an ideal 500K set can be purchased. If sample logistics is an issue then we have shown that it is possible to purchase the 500k set from only six suppliers, with a 350K set available from just three suppliers. Many large companies have been through similar exercises and have built their screening decks accordingly. If you are considering building a screening deck Ab initio then it is possible to achieve this from purchasable space. On the basis of this review we are confident that as new challenges in sample supply emerge then the market place will respond positively.
Evolution of commercially available compounds for HTS.
